发布求助
文献互助 智能选刊 最新文献

Cancer journal最新文献

筛选
英文 中文
Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma. 细胞周期检查点 p16 和 p21--高级别骨肉瘤临床病理结果的有力预测因素
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000714
Elham Nasri, Dianne E Torrence, Terrie Vasilopoulos, Jacquelyn A Knapik, Joanne P Lagmay, John D Reith, Charles Parker Gibbs
{"title":"Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.","authors":"Elham Nasri, Dianne E Torrence, Terrie Vasilopoulos, Jacquelyn A Knapik, Joanne P Lagmay, John D Reith, Charles Parker Gibbs","doi":"10.1097/PPO.0000000000000714","DOIUrl":"10.1097/PPO.0000000000000714","url":null,"abstract":"<p><strong>Purpose: </strong>In this study, we used a series of immunohistochemical measurements of 2 cell cycle regulators, p16 and p21, to evaluate their prognostic value, separately and in combination, for the disease outcomes.</p><p><strong>Method: </strong>A total of 101 patients with high-grade osteosarcoma were included in this study. Clinicopathologic data were collected, and immunohistochemistry for p16 and p21 was performed and interpreted by 3 independent pathologists. Statistical analysis was performed to assess the strength of each of these markers relative to disease outcome.</p><p><strong>Results: </strong>Our results indicate that more than 90% expression (high) of p16 by immunohistochemistry on the initial biopsy has a strong predictive value for good histologic response to chemotherapy. The patients are also more likely to survive the past 5 years and less likely to develop metastasis than patients with less than 90% p16 (low) expression. The results for p21, on the other hand, show a unique pattern of relationship to the clinicopathologic outcomes of the disease. Patients with less than 1% (low) or more than 50% (high) expression of p21 by immunohistochemistry show a higher chance of metastasis, poor necrotic response to chemotherapy, and an overall decreased survival rate when compared with p21 expression between 1% and 50% (moderate). Our results also showed that the expression of p16 and combined p16 and p21 demonstrates a stronger predictive relationship to 5-year survival than tumor histologic necrosis and p21 alone.</p><p><strong>Discussion: </strong>The results of this study, once proven to be reproducible by a larger number of patients, will be valuable in the initial assessment and risk stratification of the patients for treatment and possibly the clinical trials.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140954933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Imaging and Therapy of Differentiated Thyroid Carcinoma in Adults. 成人分化型甲状腺癌的分子成像与治疗
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000713
Philipose Getachew Mulugeta, Anthony W Chi, Thomas Michael Anderson
{"title":"Molecular Imaging and Therapy of Differentiated Thyroid Carcinoma in Adults.","authors":"Philipose Getachew Mulugeta, Anthony W Chi, Thomas Michael Anderson","doi":"10.1097/PPO.0000000000000713","DOIUrl":"10.1097/PPO.0000000000000713","url":null,"abstract":"<p><strong>Abstract: </strong>Differentiated thyroid carcinoma (DTC) has been increasing in incidence in the United States over the last several decades, although mortality rates have remained low. Radioactive iodine therapy (RAI-T) has been a mainstay of treatment for DTC since the 1940s. Imaging of DTC before and after RAI-T primarily focuses on molecular imaging of the sodium iodide symporter. The expanding understanding of the molecular profile of DTC has increased available treatment options. Incorporation of risk stratification to treatment approaches has led to deintensification of both surgical and nonsurgical treatments, leading to decreased morbidity without compromising disease control.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET Imaging for Monitoring Cellular and Immunotherapy of Cancer. 用于监测癌症细胞和免疫疗法的 PET 成像。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000722
Benjamin M Larimer
{"title":"PET Imaging for Monitoring Cellular and Immunotherapy of Cancer.","authors":"Benjamin M Larimer","doi":"10.1097/PPO.0000000000000722","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000722","url":null,"abstract":"<p><strong>Abstract: </strong>Cancer immunotherapy, including checkpoint blockade and cellular therapy, has become a cornerstone in cancer treatment. However, understanding the factors driving patient response or resistance to these therapies remains challenging. The dynamic interplay between the immune system and tumors requires new approaches for characterization. Biopsies and blood tests provide valuable information, but their limitations have led to increased interest in positron emission tomography (PET)/computed tomography imaging to complement these strategies. The noninvasive nature of PET imaging makes it ideal for monitoring the dynamic tumor immune microenvironment. This review discusses various PET imaging approaches, including immune cell lineage markers, immune functional markers, immune cell metabolism, direct cell labeling, and reporter genes, highlighting their potential in targeted immunotherapies and cell-based approaches. Although PET imaging has limitations, its integration into diagnostic strategies holds promise for improving patient outcomes and accelerating drug development in cancer immunotherapy.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Imaging of Steroid Receptors in Breast Cancer. 乳腺癌中类固醇受体的分子成像。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000715
Quinton J Keigley, Amy M Fowler, Sophia R O'Brien, Farrokh Dehdashti
{"title":"Molecular Imaging of Steroid Receptors in Breast Cancer.","authors":"Quinton J Keigley, Amy M Fowler, Sophia R O'Brien, Farrokh Dehdashti","doi":"10.1097/PPO.0000000000000715","DOIUrl":"10.1097/PPO.0000000000000715","url":null,"abstract":"<p><strong>Abstract: </strong>Steroid receptors regulate gene expression for many important physiologic functions and pathologic processes. Receptors for estrogen, progesterone, and androgen have been extensively studied in breast cancer, and their expression provides prognostic information as well as targets for therapy. Noninvasive imaging utilizing positron emission tomography and radiolabeled ligands targeting these receptors can provide valuable insight into predicting treatment efficacy, staging whole-body disease burden, and identifying heterogeneity in receptor expression across different metastatic sites. This review provides an overview of steroid receptor imaging with a focus on breast cancer and radioligands for estrogen, progesterone, and androgen receptors.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease. 治疗局部晚期或远处转移性疾病患者的一般方法。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000704
James W Smithy, Paul B Chapman
{"title":"A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.","authors":"James W Smithy, Paul B Chapman","doi":"10.1097/PPO.0000000000000704","DOIUrl":"10.1097/PPO.0000000000000704","url":null,"abstract":"<p><strong>Abstract: </strong>The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of the MAP kinase pathway has transformed the management of locally advanced and metastatic melanoma. Here, we provide a broad overview on the use of these agents in the first-line setting, incorporating a review of the clinical literature as well as the practice patterns of our respective melanoma groups. Throughout, we highlight areas of uncertainty that provide opportunities for future clinical investigation and additional improvement in outcomes for patients with melanoma.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care. 治疗标准疗法后病情进展的黑色素瘤患者的研究方法。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000702
Kylie A Fletcher, Douglas B Johnson
{"title":"Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care.","authors":"Kylie A Fletcher, Douglas B Johnson","doi":"10.1097/PPO.0000000000000702","DOIUrl":"10.1097/PPO.0000000000000702","url":null,"abstract":"<p><strong>Abstract: </strong>The advent of effective immunotherapy, specifically cytotoxic T-lymphocyte associated protein 4 and programmed cell death 1 inhibitors, as well as targeted therapy including BRAF/MEK inhibitors, has dramatically changed the prognosis for metastatic melanoma patients. Up to 50% of patients may experience long-term survival currently. Despite these advances in melanoma treatment, many patients still progress and die of their disease. As such, there are many studies aimed at providing new treatment options for this population. Therapies currently under investigation include, but are not limited to, novel immunotherapies, targeted therapies, tumor-infiltrating lymphocytes and other cellular therapies, oncolytic viral therapy and other injectables, and fecal microbiota transplant. In this review, we discuss the emerging treatment options for metastatic melanoma patients who have progressed on standard of care treatments.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Far We've Come. 我们走了多远
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000710
Mario Sznol, Jeffrey S Weber
{"title":"How Far We've Come.","authors":"Mario Sznol, Jeffrey S Weber","doi":"10.1097/PPO.0000000000000710","DOIUrl":"10.1097/PPO.0000000000000710","url":null,"abstract":"","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local and Systemic Management Options for Melanoma Brain Metastases. 黑色素瘤脑转移的局部和全身治疗方案。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000711
Afsaneh Amouzegar, Hussein A Tawbi
{"title":"Local and Systemic Management Options for Melanoma Brain Metastases.","authors":"Afsaneh Amouzegar, Hussein A Tawbi","doi":"10.1097/PPO.0000000000000711","DOIUrl":"10.1097/PPO.0000000000000711","url":null,"abstract":"<p><strong>Abstract: </strong>Development of brain metastasis is one of the most serious complications of advanced melanoma, carrying a significant burden of morbidity and mortality. Although advances in local treatment modalities such as stereotactic radiosurgery and breakthrough systemic therapies including immunotherapy and targeted therapies have improved the outcomes of patients with metastatic melanoma, management of patients with melanoma brain metastases (MBMs) remains challenging. Notably, patients with MBMs have historically been excluded from clinical trials, limiting insights into their specific treatment responses. Encouragingly, a growing body of evidence shows the potential of systemic therapies to yield durable intracranial responses in these patients, highlighting the need for inclusion of patients with MBMs in future clinical trials. This is pivotal for expediting the advancement of novel therapies tailored to this distinct patient population. In this review, we will highlight the evolving landscape of MBM management, focusing on local and systemic treatment strategies.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic Melanoma Treatment in Special Populations. 特殊人群的转移性黑色素瘤治疗。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000701
Madeline Miceli, Christina Boatwright, Janice M Mehnert
{"title":"Metastatic Melanoma Treatment in Special Populations.","authors":"Madeline Miceli, Christina Boatwright, Janice M Mehnert","doi":"10.1097/PPO.0000000000000701","DOIUrl":"10.1097/PPO.0000000000000701","url":null,"abstract":"<p><strong>Abstract: </strong>This review outlines the most up-to-date metastatic melanoma treatment recommendations and relevant risks for patients with solid organ transplants, patients with renal dysfunction, and patients with preexisting autoimmune conditions. These specific treatment populations were excluded from the original clinical trials, which studied immune checkpoint inhibitors and BRAF/MEK inhibitors in the advanced melanoma setting. We have synthesized the current body of literature, mainly case series and retrospective analyses, to reflect the evidence for the treatment of these special patient populations at present.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma. 治疗转移性黑色素瘤的肿瘤浸润淋巴细胞及其他细胞疗法。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000705
Christy Los, Sebastian Klobuch, John B A G Haanen
{"title":"Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma.","authors":"Christy Los, Sebastian Klobuch, John B A G Haanen","doi":"10.1097/PPO.0000000000000705","DOIUrl":"10.1097/PPO.0000000000000705","url":null,"abstract":"<p><strong>Abstract: </strong>Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing patients, their prognosis is still dismal. Based on clinical trial data, treatment with adoptive cell therapies holds great promise. In patients with metastatic melanoma progressing on or nonresponsive to single-agent anti-programmed cell death 1, infusion of tumor-infiltrating lymphocytes can produce responses in up to half of patients, with durable complete responses in up to 20%. Genetic modification of peripheral blood T cells with T-cell receptors derived from tumor-specific T cells, or with chimeric antigen receptors, has the potential to further improve treatment outcomes in this refractory population. In this review, we will discuss the historical development, current status, and future perspectives of adoptive T-cell therapies in melanoma.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信